Infections and Infectious Diseases | Phase II Developments | CHINA

Ascentage Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Ascentage Pharma Dosed First Patient in Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for Chronic Hep B

Lead Product(s): APG-1387,Entecavir

Therapeutic Area: Infections and Infectious Diseases Product Name: APG-1387

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

The global multi-center, open-label Phase II study is designed to evaluate the safety and efficacy of APG-1387 in combination with entecavir in patients with CHB who are treatment-naive or -experienced.

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development

Lead Product(s): CoronaVac

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Advantech Capital

Deal Size: $15.0 million Upfront Cash: Undisclosed

Deal Type: Funding May 22, 2020

Details:

The Funding will provide the Company with the necessary resources to continue its development of an inactivated vaccine against COVID-19 named CoronaVac.

Sinopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

China's Inactivated COVID-19 Vaccine Enters 2nd-Phase Clinical Trial

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2020

Details:

96 persons in three age groups have received the vaccine in the first phase of clinical trial as of April 23. The vaccine has shown good safety so far and vaccine receivers are still under observation.

Ascletis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Ascletis Receives IND Approval for its HIV Drug ASC09F

Lead Product(s): ASC09,Ritonavir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 13, 2020

Details:

Company got IND approval from National Medical Products Administration (NMPA) for its human immunodeficiency virus (HIV) protease inhibitor ASC09F (ASC09/Ritonavir Fixed-Dose Combination).

CanSino Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data

Lead Product(s): Ad5-nCoV

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 10, 2020

Details:

Based on the preliminary safety data of the phase I trial for Ad5-nCoV, the Company and Academy of Military Medical Sciences plan to initiate phase II clinical trial for Ad5-nCoV in China.

TenNor Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

TenNor Therapeutics Received FDA Orphan Drug Designation

Lead Product(s): TNP-2092

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 20, 2020

Details:

TenNor has completed a Phase II clinical trial for TNP-2092 in the United States for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and received positive results.

Find

Find Drugs for Infections and Infectious Diseases in Phase II Clinical Development in CHINA

China

Product Type

Companies

Ascentage Pharma

Ascentage Pharma Dosed First Patient in Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for Chronic Hep B

Sinovac Biotech

Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development

Sinopharm

China's Inactivated COVID-19 Vaccine Enters 2nd-Phase Clinical Trial

Ascletis Pharma

Ascletis Receives IND Approval for its HIV Drug ASC09F

CanSino Biologics

China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data

TenNor Therapeutics

TenNor Therapeutics Received FDA Orphan Drug Designation